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Abstract
Background: This trial aims to investigate the effectiveness and cost implications of 'pharmaceutical care'
provided by community pharmacists to elderly patients in the community. As the UK government has
proposed that by 2004 pharmaceutical care services should extend nationwide, this provides an
opportunity to evaluate the effect of pharmaceutical care for the elderly.
Design: The trial design is a randomised multiple interrupted time series. We aim to recruit 700 patients
from about 20 general practices, each associated with about three community pharmacies, from each of
the five Primary Care Trusts in North and East Yorkshire. We shall randomise the five resulting groups of
practices, pharmacies and patients to begin pharmaceutical care in five successive phases. All five will act
as controls until they receive the intervention in a random sequence. Until they receive training community
pharmacists will provide their usual dispensing services and so act as controls.
The community pharmacists and general practitioners will receive training in pharmaceutical care for the 
elderly. Once trained, community pharmacists will meet recruited patients, either in their pharmacies (in 
a consultation room or dispensary to preserve confidentiality) or at home. They will identify drug-related 
issues/problems, and design a pharmaceutical care plan in conjunction with both the GP and the patient. 
They will implement, monitor, and update this plan monthly. The primary outcome measure is the 
'Medication Appropriateness Index'. Secondary measures include adverse events, quality of life, and patient 
knowledge and compliance. We shall also investigate the cost of pharmaceutical care to the NHS, to 
patients and to society as a whole.
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What is the problem to be addressed?
Up to 80% of elderly people may receive inappropriate
therapy [1,2]. This includes over-treatment, causing
adverse drug reactions [3] and under-treatment, e.g. for
atrial fibrillation [4]. In the UK over-treatment is often
due to the process of repeat prescribing. About 75% of all
prescribed items are 'repeats' [5], that is items issued with-
out the patient seeing the doctor. Doctors review only
about 75% of these [6]. As a result elderly people are more
likely to experience drug-related adverse events [7-9].
Thus they are more in need of improved prescribing than
younger age groups.
In England the net drug cost for elderly people (those aged
60 and over) was £2,000 million in 1998 [10]. On average
they had 3.6 times more prescriptions than younger
adults (those aged 15–59 years). Additionally the percent-
age aged 75 or over of the UK population will double by
2020 [11]. This unprecedented age distribution will have
profound effects on society and its institutions, including
health care [12].
In the US Hepler and Strand [13] proposed a system of
'pharmaceutical care' (PC). In this system, while doctors
continue to take ultimate care of patients, pharmacists are
responsible for moderating their drug care. In doing so
pharmacists co-operate with doctors, patients and carers
in designing, implementing and monitoring a 'pharma-
ceutical care plan' (PCP) [e.g. Table 1]. By involving
patients in decision-making, PC aims to improve commu-
nication, promote compliance and concordance with
treatment, and achieve specified therapeutic outcomes.
This has the potential to reduce the drug bill and drug-
related problems, and improve patients' quality of life.
In the UK Lord Hunt (then Parliamentary Under-Secretary
of State for Health) recognised that the clinical skills of
pharmacists have long been underused [14]. In contrast
the workload of general practitioners (GPs) has been ris-
ing in recent years. Hence using community pharmacists
to manage the medication of elderly patients will ration-
alise the use of human resources in community health
care. Furthermore US studies have shown that better pre-
scribing reduces drug-related problems in hospital [15],
drug costs [16] and thus the health care budget. However
there has been insufficient information to conduct a full
economic analysis. The proposed trial will provide better
economic information for policy makers and the phar-
macy profession in the UK.
What are the principal research questions to be addressed?
A Is shared pharmaceutical care for elderly people in the
community effective in:
i improving the quality of prescribing?
ii improving patient's knowledge about their disease and
medication?
iii improving compliance?
iv reducing adverse events?
v and thus improving quality of life?
B Is shared pharmaceutical care for elderly people in the
community cost-effective?
Table 1: Extract from a pharmaceutical care plan completed in the feasibility study
Drug Dose, frequency, 
quantity
Indication Potential drug related 
problems
Suggested action For use by GP
Amiodarone tabs 100 mg, od, 28 ?arrhythmia Deposits in eye, SOB, 
peripheral neuropathy
No change
Aspirin tabs 75 mg, 2 od, 56 2° prevention CHD GI effects No change (could reduce to 
75 mg od)
Diclofenac tabs 50 mg, bd, 56 Pain GI effects, dizziness, vertigo Stop – no benefit
Tylex® caps 2, qds,100 Pain Constipation Stop – no benefit
Isphagula husk 3.5 g, bd, 30 Constipation Patient not taking sufficient 
fluid for effective use
Stop – exacerbates 
dehydration, unpalatable, 
prefers senna
Lactulose liq mdu, 300 ml Constipation Patient not taking sufficient 
fluid for effective use
Stop – finds senna more 
effective
Ranitidine tabs 150 mg, bd, 60 ?dyspepsia GI effects, dizziness, 
confusion, tiredness
Leave existing stocks for use 
prn
Tamsulosin MR tabs 400 mg, od, 30 Enlarged prostate Dizziness, hypotension, 
drowsiness
No changePage 2 of 14
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The UK is facing unprecedented growth in the number of
elderly people. So the Department of Health [17] has pre-
pared the National Service Framework for the Elderly to
improve health care for elderly people. In May 2000
research funders including the Department of Health,
Medical Research Council, Biotechnology Biological Sci-
ences Research Council and Engineering and Physical Sci-
ences Research Council announced plans to develop a co-
ordinated approach to ageing research by forming the
Ageing Research Funders Forum. The Forum intends to
stimulate and facilitate multi-disciplinary research to
improve the health of elderly patients.
The Royal Pharmaceutical Society of GB [RPSGB] [18] and
the UK Clinical Pharmacy Association [UKCPA] [19] both
recommend that UK pharmacists provide 'pharmaceutical
care' for their patients. More specifically the Crown report
[20] recommends that pharmacists take on the extra role
of looking after the long-term drug treatment of patients.
Although the pharmacy profession has started to adopt
this extended role, there is insufficient rigorous evidence
to substantiate this practice. Hence the proposed trial will
be important in underpinning these political and profes-
sional initiatives.
Most recently the Department of Health [21] has pro-
posed that Primary Care Trusts (PCTs) across England
should invest in pharmaceutical care services giving
patients access to more help from pharmacists in using
their medicines. Consequently pharmacy practice in the
community may be completely transformed by 2004.
Hence there is a 'window of opportunity' for a ran-
domised trial to evaluate the effectiveness and cost-effec-
tiveness of pharmaceutical care provided by community
pharmacists.
More specifically RESPECT will study the co-operation
needed between community pharmacists and GPs. The
Royal Pharmaceutical Society of Great Britain fully sup-
ports this trial and believes it will provide vital scientific
evidence for the development of the pharmacy profession
within primary health care.
Two recent local developments have helped us to build
research infrastructure and capacity, and thus facilitate the
proposed trial. First the East Riding Health Authority
funded three of us (IW, HE & PDC) to undertake a feasi-
bility study of pharmaceutical care. This focused on 'vul-
nerable' people, defined as elderly people who were
housebound, living alone, mentally ill, or recently dis-
charged from hospital. Fourteen pharmacies offered phar-
maceutical care to all general practices within two PCTs –
Eastern Hull (urban) and East Yorkshire (rural). This fea-
sibility study enabled us to assess patient cooperation in
research and the logistics of undertaking such research.
Because many practices in East Yorkshire are dispensing
practices, two pharmacists worked directly with these
practices to provide pharmaceutical care but not medica-
tion. Without formal training pharmacists adapted phar-
maceutical care to British primary health care and tested
the use of PCPs in collaboration with GPs. Preliminary
analysis suggests that pharmaceutical care is entirely feasi-
ble and merits rigorous evaluation. The PCP in Table 1
illustrates its potential. Although recruitment was slow,
we identified two reasons for this – the lack of research
costs for GPs and the shortage of treatment costs for phar-
macists. In designing and costing RESPECT we have
addressed and, we believe, overcome both problems. We
have also developed a training programme for commu-
nity pharmacists, focusing on the clinical content of phar-
maceutical care, and on collaboration with GPs.
Secondly another of us (HE) received a grant from NHS
Northern & Yorkshire to deliver a training programme to
build up the research capacity of East Riding and Hull
community pharmacists. This funding has helped us to
prepare community pharmacists to take on the proposed
trial, and to overcome the problems we have identified.
Relevant systematic reviews and the need for a trial
Numerous articles have discussed pharmaceutical care
and 'medicines management' (which some British
researchers regard as a synonym for pharmaceutical care)
[22]. Two systematic reviews [23,24] of pharmaceutical
care and medicines management report that only eight
papers, all from the US, report randomised studies [15,25-
31]. Only one was in primary health care [30]. Another
review shows that none of the studies met accepted phar-
maco-economic criteria [32]. All three reviews recom-
mended more randomised trials to evaluate
pharmaceutical care.
To extend these reviews in response to comments on our
application to the Medical Research Council, in particular
to identify newly published or current research, we
adopted five distinct strategies. First we conducted our
own systematic search of the Cochrane Library, Embase,
EPIC and International Pharmaceutical Abstracts (IPA).
We based our search strategy for Embase, EPIC and IPA on
the algorithm: (pharmaceutical care OR pharmaceutical
service* OR ambulatory care clinical OR ambulatory care
pharmac* OR clinical pharmac* OR clinical pharmacy
program* OR clinical pharmacy specialis* OR commu-
nity pharmac* OR comprehensive pharmaceutical serv-
ice* OR medic* management OR patient oriented
service* OR pharmac* intervention* OR pharmac*-man-
aged clinic* OR polypharmacy OR polytherapy OR repeat
dispens* OR repeat medic* OR repeat prescription) AND
(elderly OR aged OR old OR geriatric). We found six morePage 3 of 14
(page number not for citation purposes)
BMC Health Services Research 2004, 4 http://www.biomedcentral.com/1472-6963/4/11randomised trials on pharmaceutical services or medi-
cines management for the elderly [33-38]. However none
evaluated pharmaceutical care for the elderly as we have
defined it. Furthermore only Bond's study of repeat dis-
pensing was conducted in British primary health care.
Secondly we searched the current European Union
BIOMED database. We identified a recently completed
multi-national study of pharmaceutical care for elderly
patients in the community. The UK arm in Northern Ire-
land includes about 100 patients in the intervention
group. Though only interim results were available (McEl-
ney, personal communication), preliminary findings were
encouraging [39]. As health care varies across the EU,
however, it is unlikely that the rest of the project is rele-
vant to British primary health care.
Thirdly we searched the current UK National Research
Register using the search term 'pharmacy'. We identified
seven continuing randomised studies. In one study of
patients with coronary heart disease community pharma-
cists are drawing up care plans [40]. Another four are trials
of medication review programmes undertaken by hospital
pharmacists, practice pharmacists (pharmacists working
in GP surgeries) or research pharmacists rather than tradi-
tional community pharmacists (Nazareth, Reid, Thomas,
Zermansky). The remaining two interventions cannot be
classified as pharmaceutical care or medicines manage-
ment (Barber, Peat).
Fourthly we contacted the 16 current Schools of Pharmacy
in the UK to seek other pharmaceutical care projects. We
identified two randomised studies at Robert Gordon Uni-
versity using practice pharmacists to run 'medication
review clinics' in GP surgeries rather than community
pharmacists in their own pharmacies. Other Schools of
Pharmacy have confirmed that no study has been or is
being conducted except that in Northern Ireland [39].
Finally we contacted known experts in pharmaceutical
care – Dr Susan Ambler (RPSGB), Professor Alison
Blenkinsopp (University of Keele), Professor Joseph
Hanlon (University of Minnesota), Dr Janet Krska (Col-
lege of Pharmacy Practice), Professor James McElney
(Queen's University Belfast), and Dr Foppe Van Mil
(Pharmaceutical Care Network Europe Foundation). This
identified four more trials [41-44].
Most of the 19 completed trials have reported positive
findings including improved knowledge of and adherence
to treatment, improved biochemical outcomes, and even
reduced mortality in heart failure. However only two
addressed the economics of pharmaceutical care and
medicines management [31,38].
In summary the literature suggests that pharmaceutical
care can benefit patients. As the majority of randomised
studies were in the US, their relevance to the UK is limited.
Furthermore very few were in community pharmacies,
and only two related to elderly patients in the UK [39,42].
So the evidence about the effectiveness of 'pharmaceutical
care' within British primary care remains weak.
Nevertheless PC is being promoted by all the pharmaceu-
tical organisations – National Pharmaceutical Associa-
tion, Pharmaceutical Services Negotiating Committee
[45], RPSGB [18,46] and UKCPA [19]. To implement this
advice without more evidence would therefore create an
'evidence gap'. Usual practice would diverge from the
objective evidence [47]. Nevertheless the NHS plan and its
pharmacy sequel [17,21] proposed alternative contracts
for "personal medical services-like schemes" such as med-
icines management, pharmaceutical care and repeat pre-
scribing provided by community pharmacists. However
our literature review has shown that practice or research
pharmacists based in clinics, rather than community
pharmacists based in their pharmacies, have conducted
most of the relevant research. Hence there is an urgent
need for large studies to evaluate the effectiveness of phar-
maceutical care and the use of PCPs in British primary
care.
How will the results of this trial be used?
This study will provide policy makers and the pharmacy
profession with information about the practicality and
effectiveness of pharmaceutical care in British primary
care. It will estimate the benefits and costs of pharmaceu-
tical care in this context and provide information for the
Department of Health to develop an appropriate remu-
neration formula. In short the study will provide evidence
to guide the future implementation of pharmaceutical
care in the UK and thus encourage 'evidence-based phar-
macy practice'.
Risks to the safety of patients in the trial?
This is a pragmatic trial with very little risk to patients.
Those receiving pharmaceutical care will be at no greater
risk than in normal clinical practice. Thus there is no need
for an (independent) Data Monitoring and Ethics Com-
mittee. Instead two (statutory) Local Research Ethic Com-
mittees (LREC) – Hull & East Riding and Selby & York
LREC – have given ethical approval.
Design
Brief summary
In PC doctors continue to take ultimate care of patients
and pharmacists are responsible for moderating their drug
care, in particular by designing, implementing and moni-
toring a PCP. Our feasibility study of PC in fourteen phar-
macies in Eastern Hull and East Yorkshire Primary CarePage 4 of 14
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and merited rigorous evaluation. We are therefore
expanding the size and scope of our research within a ran-
domised multiple interrupted time series design. We are
collecting data on prescribing and resource use from
about 20 general practices and about 60 pharmacies and
on health outcomes from 400 patients.
What is the proposed trial design?
The Medical Research Council (MRC) has defined 'com-
plex interventions in health care' as "interventions com-
prising separate elements which seem essential to the
proper functioning of the intervention although the effec-
tive ingredient is difficult to specify" [48]. PC is an arche-
typal complex intervention. The MRC has identified five
essential steps in the evaluation of such an intervention –
theory, modelling, exploratory trial, definitive ran-
domised trial and long-term implementation [48]. A
definitive trial must be generalisable in the sense that it
recruits a range of patients or conditions across a number
of centres. It must also be 'pragmatic' in the sense that it
evaluates the complex intervention in routine clinical
practice and in a form close to that in which implementa-
tion is likely in the long term [49]. In contrast exploratory
trials evaluate complex interventions in controlled exper-
imental conditions and in a prototype or idealised form
[49]. Of the 19 trials summarised previously most are
exploratory, few definitive. Thus it is a pragmatic multi-
centre trial that PC now needs.
It is difficult to design a pragmatic trial for PC that ran-
domises individual patients [50]. Both GPs and pharma-
cists learn the relevant techniques cumulatively, with the
result that those who use these techniques for experimen-
tal patients cannot readily withhold them from control
patients. It follows that randomisation must be by 'clus-
ters' of patients, for example patients associated with a
practice or pharmacy. Unfortunately practices and phar-
macies are rarely coterminous. Hence if we take practices
as the clusters to be randomised, then neighbouring phar-
macies will serve some patients randomised to PC and
others randomised to usual care. Thus there will be con-
tamination within pharmacies. Similarly if we take phar-
macies as clusters, there will be contamination within
practices. We conclude that PCTs are the most appropriate
clusters for randomisation. Our feasibility study lent sup-
port to this analysis. Encouraged by the recent establish-
ment of the Hull York Medical School [51], we have
therefore recruited five PCTs in North and East Yorkshire
to take part – Eastern Hull, East Yorkshire, Selby & York,
West Hull, and Yorkshire Wolds & Coast.
If we select half of the PCTs at random for training in
pharmaceutical care, there is a real danger that the other
half will suffer from 'resentful demoralisation' [52]. At the
very least, therefore, the second half should receive train-
ing at the end of the trial. Fortunately we can do even bet-
ter by phasing the training in PCTs in a random order, as
shown in Figure 1. Because each PCT has a period before
training to compare with the period after training, each
can act as its own control. This design, known as a ran-
domised multiple interrupted time series [52], has three
major advantages:
a organisational – because training needs fewer resources
over a longer period;
b statistical – because it is more powerful; and
c epidemiological – because staggering the introduction
of PC across PCTs helps to protect the evaluation from
potentially contaminating changes in health and other
policies by ensuring that such changes affect different
PCTs at different stages of the cycle of developing PC.
Our feasibility study also suggested that within each PCT
we could recruit at least four general practices and about
three community pharmacies associated with each prac-
tice – about 20 practices and 40 pharmacies in all. We
have randomised the resulting five clusters of practices,
pharmacies and patients to begin pharmaceutical care in
five successive waves. All five stay in the control group
until they receive the intervention in a random sequence.
What are the planned trial interventions?
Intervention group
The experimental intervention is PC, in which pharma-
cists co-operate with doctors, patients and carers in
designing, implementing and monitoring a PCP for exam-
ple Table 1. The London and Bradford schools of phar-
macy are providing five blocks of training, each consisting
of one workshop for community pharmacists on PC for
the elderly and one joint workshop for pharmacists and
GPs on how to work together. GPs and community
pharmacists in the same PCT attend the same training
block (Figure 1)). The workshops encourage them to
adopt a problem-based approach to the application of
pharmaceutical care. In particular they enable pharma-
cists to assess patients' pharmaceutical care, to withdraw
unwanted medicines, and to draw up PCPs. The training
also enables GPs to work with PCPs. Hence these work-
shops are accredited for both professions. They also take
account of experiences with our feasibility study. Thereaf-
ter with the support of Bradford School of Pharmacy and
Hull Postgraduate Medical School we shall extend the
function of Hull and East Riding Pharmacy Development
Group and establish a local PC network to support all par-
ticipating pharmacists and GPs.Page 5 of 14
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patients. Although few pharmacists previously provided
PC in the way we are training pharmacists, they often had
private conversations with patients in a separate room. PC
is building on these existing arrangements. Participating
pharmacists have professional discretion, either to inter-
view patients in the pharmacy or to visit them at home.
This pragmatic choice enhances the external validity of
RESPECT.
The community pharmacists follow the following steps to
develop the PCP (adapted from Strand et al 1992) [53]:
A Establish pharmacist-patient relationship.
B Collect, synthesise and interpret relevant information
on patient, disease and drug, working with GP and
patient.
C Define and rank drug-related problems ["an event or
circumstance involving a drug treatment that (potentially)
prevents a patient experiencing an optimum outcome of
medical care" – Strand et al 1990] [54]:
i Failure to receive drug: the patient has a medical prob-
lem that resulted from his or her not receiving a drug.
ii Untreated indication: the patient has a medical problem
that requires drug therapy (an indication for drug use) but
is not receiving a drug for that indication.
Timetable of the RESPECT trialF gure 1
Timetable of the RESPECT trial
2002 2003 2004 2005 
J F M A M J J A S O N D J F M A M J J A S O N D J F M A M J J A S O N D J F M A M J J A S 
PCT 
   1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 
TM 
Train 
+ 
Base 
Intervention  
E
as
te
rn
 H
u
ll
 
Assistance 
and 
Materials Id
en
ti
fy
 
Recruit 
 
Control 
(3 month) 
 M3  
M12  
Final Data 
Collection + 
MAI 
 
Analysis + Reporting 
 
Train 
+ 
Base 
Intervention  
Y
o
rk
s 
W
o
ld
s 
&
 C
o
as
t 
  
Assistance 
and 
Materials Id
en
ti
fy
 
Recruit 
Control 
(5 month) 
  M3  
M12  
Final Data 
Collection + 
MAI 
 
Analysis + Reporting 
 
Train 
+ 
Base 
Intervention  
E
as
t 
Y
o
rk
sh
ir
e 
Assistance 
and 
Materials Id
en
ti
fy
 
Recruit 
Control 
(7 months) 
  M3  
M12  
Final Data 
Collection + 
MAI 
 
Analysis + Reporting 
 
Train 
+ 
Base 
Intervention  
S
el
b
y
 &
 Y
o
rk
 
Assistance 
and 
Materials Id
en
ti
fy
 
Recruit 
Control 
(9 months) 
  M3  
M12  
Final Data 
Collection + 
MAI 
 
Analysis + Reporting 
 
Train 
+ 
Base 
Intervention   
W
es
t 
H
u
ll
 
Assistance 
and 
Materials 
Id
en
ti
fy
 
Recruit 
Control 
(11months) 
  M3  
M
1
2 
 
Final Data 
Collection 
+ MAI 
 
Analysis + Reporting 
 
Key 
Assistance and Materials:  Recruit researchers.  Recruit general practices and community pharmacists in all 5 Primary Care Trusts (PCTs).  Prepare and pilot trial 
materials. 
Identify:   Identify patients in East Riding.  Pilot trial materials. 
Recruit:   Recruit patients in all 5 PCTs.  Randomise PCTs.  Measure recruitment outcomes.  Manage data. 
TM Research Pharmacist to finish preparing training materials, pharmaceutical care manual and Medication Appropriate Index (MAI).    
Control:    Control period. 
Train + Base    Training for GPs and pharmacists + Measure baseline outcomes prior to the start of intervention (2 month chase-up) 
Intervention:    Intervention period.   
MAI    Extract retrospective data from GP practices (e.g. MAI).   
M3     Measure outcomes at 3 months from the start of intervention, allowing up to 2 months to chase questionnaire returns. 
M12:     Measure outcomes at 12 months from the start of intervention: indicated in table by M12, allowing 2 months chase up. 
Final Data Collection:   Measure outcomes at 30-35months (roughly 2 ½ years) after the start of recruitment.  Home visits + MAI data. 
Analysis and Reporting:  Data analysis and reporting.   Page 6 of 14
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tion but is taking the wrong drug.
iv Sub-therapeutic dosage: the patient has a problem that
is being treated with too little of the correct drug.
v Overdosage: the patient has a medical problem that is
being treated with too much of the correct drug.
vi Adverse drug reaction: the patient has a medical prob-
lem that stems from an adverse reaction to a drug.
vii Drug interaction: the patient has a medical problem
that is the result of a drug-drug or drug-food interaction.
viii Drug use without indication: the patient is taking a
drug for which there is no medically valid indication.
D Establish therapeutic goals for each drug-related prob-
lem with patient and GP.
E Identify feasible alternative treatments.
F Select the best pharmaceutical solution and decide with
patient the best drug, formulation and dose.
G Agree pharmaceutical care plan with both patient and
GP (e.g. Table 1).
H Implement and monitor plan.
I Follow up and measure outcome.
In addition pharmacists educate patients and, if appropri-
ate, carers about the indication for each medication and
its use, and withdraw unwanted medicines with patients'
consent. If patients need compliance aids such as dosette
boxes or reminder charts, the pharmacists provide these
services. They continue to update and implement the PCP,
and monitor outcome at least monthly in association with
patients and their GPs.
The patient has a Study Membership Card to remind hos-
pital staff to contact the patient's community pharmacist
when the patient is admitted to and discharged from hos-
pital. The community pharmacists can then change the
patient's PCP accordingly and avoid drug-related prob-
lems arising from miscommunication after hospital dis-
charge. If patients are unable to visit the pharmacy, for
example after hospital discharge, pharmacists should
arrange a domiciliary visit to provide the pharmaceutical
care.
We are monitoring the process of pharmaceutical care by
collecting PCPs and analysing pharmacists' time sheets,
continuing education records and professional develop-
ment portfolios.
Although patients have the right to take their prescriptions
to any pharmacy for dispensing, there is evidence that
more than 80% consistently use the same pharmacy. To
facilitate pharmaceutical care, we encourage, but not
require, them to do so. As PC is time-consuming, how-
ever, it is unlikely that a second pharmacy would dupli-
cate the plan. As the potential use of more than one
pharmacy is an inevitable part of this complex interven-
tion, this pragmatic arrangement will enhance external
validity.
If a trained pharmacist leaves a participating pharmacy,
we shall give individual training to his or her successor –
another example of the pragmatic nature of this trial.
Control group
Until they receive training and join the intervention
group, community pharmacists provide their usual dis-
pensing service and so act as controls. At this stage phar-
macists do not know which patients have consented to
join the trial.
What are the proposed arrangements for allocating 
patients to trial groups?
The PCT is the natural unit within which to train and sup-
port community pharmacists and GPs in PC care and to
allocate this intervention in sequence. One of us (PDC)
wrote to all practices in the five PCTs, outlining the
project, making clear the nature of the working agreement
between practices, associated community pharmacies,
and the project team, and inviting expressions of interest.
From those responding in each PCT who are close to
potential participating pharmacies, we recruited a sample
of at least four practices after stratifying for number of
partners and about 60 associated pharmacies. When
appropriate we recorded reasons given by practices and
pharmacies for not taking part. Recruited practices then
helped us recruit samples of about 35 eligible patients,
depend on the size of the practice, the sampling method
varies:
a) For smaller practices (consisting of one or two partners)
with less than 100 patients there was no sampling. For
practices with over 100 eligible patients sampling (strati-
fied by age and the number of drugs) was completed. A
list of eligible patients was obtained from the practice
computer record and from them a random sample of up
to 100 patients was obtained. This list was given to the
GPs to obtain their consent for researchers to approach
those patients concerned. Following this each patient was
written to and where appropriate a meeting arranged withPage 7 of 14
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in the trial was therefore the patients choice.
b) For larger practices (consisting of three or more part-
ners) – sampling (stratified by age and total number of
drugs) was undertaken if there were more than 200 eligi-
ble patients. A list of eligible patients was obtained from
the practice computer and the GPs were then asked to pro-
vide consent for researchers to approach a maximum of
200 patients. Again the decision to participate in the trial
involved choice on the part of those patients concerned.
There is conflicting evidence whether age is a risk factor
for drug-related adverse events [55-57]. Fortunately strati-
fication is a technique that generally yields statistical
gains, but not costs.
In principle we did not restrict the pharmacies that could
volunteer for RESPECT. This pragmatic approach
enhances external validity, especially if pharmacists can
volunteer to provide PC in future. In practice we sampled
general practices after stratifying by size. This limited the
final sample of participating pharmacies to those associ-
ated with sampled practices. Whether a pharmacy is inde-
pendent or part of a chain is a potential covariate in our
eventual multi-level analysis. Both our palliative
pharmaceutical care study [58] and our feasibility study
have shown that single-handed pharmacists can provide
PC. However both studies have also shown that resource
constraints limit the numbers of patients in PC at any
time. The NHS treatment costs available within RESPECT
have helped to address this hurdle.
What are the proposed methods for protecting against 
other sources of bias?
Blinding is not possible for pharmacists, GPs or patients
because the nature of the intervention requires their full
knowledge. However pharmacists do not know which
patients have been recruited into the trial until they
receive training and join the intervention group. Further-
more patient questionnaires are self-administered or
administered by the research pharmacist and trial co-ordi-
nator rather than pharmacists or GPs. Finally the assessors
of one of the main outcome measures, the Medication
Appropriateness Index will remain blind throughout.
The trial co-ordinator and research pharmacist used prac-
tice computer records to identify potential trial partici-
pants and asked GPs to give consent. Although GPs
withheld consent for some patients, the research staff
asked for reasons. (To identify, and if necessary adjust for,
selection bias we shall also compare the personal charac-
teristics of all consented and non-consented patients.)
The research staff then invited potential participants into
the trial using practice headed letters and visits to practice
or home.
What are the planned inclusion and exclusion criteria?
Inclusion criteria
Patients aged more than 75 years with repeat prescriptions
for five or more drugs (excluding drugs taken only when
required), who are living at home, well oriented in time
and place, and able to give their consent to take part.
Abbreviated Mental Test is used to confirm patients' men-
tal state, patients score 7 or above (out of 10) will be
included. Their GPs' consent is also necessary.
Exclusion criteria
Patients in residential or nursing homes. Patients who
took part in our feasibility study of vulnerable elderly peo-
ple or who normally use a pharmacy which has refused to
participate in the trial. Patients with memory impairment
who score 6 or below on the Abbreviated Mental Test.
What is the proposed duration of treatment period?
12 months (Figure 1)
What is the proposed frequency and duration of follow up?
We plan to observe patients for 36 months between
recruitment and final visit (Figure 1). We have asked them
to provide data at recruitment, at the beginning of phar-
maceutical care and three and 12 months thereafter, and
at the final visit 36 months after recruitment. We have
asked their practices and pharmacies to provide access to
their medical records at the end of the study.
What are the proposed outcome measures?
Primary
Medication Appropriateness Index
Secondary
Patients' knowledge, compliance and concordance, prac-
tice-reported (and therefore more serious) adverse events,
and self-assessed health outcome
Economic
Cost of treatment to NHS, patients and society as a whole
How will the outcome measures be measured at follow-up?
Medication Appropriateness Index (MAI)
The MAI was devised by Hanlon [59] to measure the
appropriateness of medication, validated by Samsa [60]
and Schmader [61], and successfully used within a ran-
domised trial by Hanlon [15]. The resulting score depends
on the number of drugs regularly taken by the patient and
the assessed appropriateness of each. In this study we shall
use blinded and independent (though paid) clinical phar-
macists to assess the appropriateness of drugs prescribed
within the trial. Clinical pharmacologists andPage 8 of 14
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will use the information available from patient medical
records at recruitment, at the beginning of pharmaceutical
care and three and 12 months thereafter, and at the final
visit 36 months after recruitment. The research pharmacist
and trial co-ordinator will collect these data from the
records of participating practices, including their repeat
prescription indices, electronically wherever possible. By
designing the panel assessment forms for electronic scan-
ning we shall quickly identify patients about whom the
assessors disagree. They will then meet to resolve such dif-
ferences. Although the MAI is an intermediate outcome, it
is correlated with the absence of adverse reactions and
interactions. We shall investigate whether it is also corre-
lated with better patient outcomes. Few British studies
have used the MAI. We shall therefore use psychometric
methods [62] to revalidate it for the UK. Meanwhile we
are undertaking a feasibility study to compare scores
within and between expert professionals.
Knowledge, compliance, adverse events and health outcomes
Research staffs are monitoring knowledge, compliance,
adverse events and self-assessed health outcomes in all
trial patients over the duration of the study. Depending on
the mental state and accessibility of the patient they use
patient-completed questionnaires, telephone interviews
or home interviews – at recruitment, at the beginning of
pharmaceutical care and three and 12 months thereafter,
and at the final visit 36 months after recruitment. There is
evidence that method of completion affects health out-
come measures [63,64]. To prevent this affecting the inter-
nal validity of the trial we shall check that the proportions
of patients using the three modes of completion are con-
sistent across both PCTs and time. If necessary we shall
use analysis of covariance to adjust for any imbalance in
these proportions.
Compliance and patients' knowledge of medication
We ask patients to complete a questionnaire to measure
compliance, originally devised by researchers at Keele
University. Before its use in RESPECT we are enhancing
and revalidating it
Pharmacists ask patients how they take each drug during
pharmaceutical care. We shall calculate the proportion of
medications for which their response agrees with the
directions on the records in the pharmacy or practice [15].
For patients with at least six months' continuous drug
records we shall calculate expected percentage compliance
from the expected finish date for each prescription and the
date on which the next prescription was filled. We are
using general practice data to validate pharmacy records,
particularly important during the control period.
We use tablet counts as a further measure of compliance.
We ask pharmacists to request patients to bring all tablets
to the pharmacy at the start and end of the intervention.
The pharmacist conducts a tablet count on both occa-
sions. If a patient is housebound, the pharmacist visits the
patient's home. Pharmacists also ask patients about the
indications for the medication, using questions like "what
is this drug for?" or "how does this drug help?" To meas-
ure patients' knowledge of medication we shall calculate
the proportion of drugs for which they give a correct
response, based upon their medical problems and
accepted indications for prescribing each drug [15].
To validate pharmacists' tablet counts and patients'
knowledge about medication, researchers conduct further
tablet counts and ask samples of patients about indica-
tions for medications on two separate occasions. At
recruitment and at the start of the intervention they visit a
1 in 5 stratified random sample of patients at home and
count their supply of tablets. This sample of approxi-
mately 140 patients consists of 70 housebound patients
and 70 patients able to visit the practice. They visit a sec-
ond stratified random sample of 140 patients and count
their tablets at the start of the intervention and at either
three or twelve months thereafter, selected at random.
Adverse events
Throughout the study we collect data from general prac-
tices on serious adverse events, consultations in primary
care, and hospital referrals and admissions. We define a
serious adverse event as one that carries a risk of death or
persistent or significant disability or incapacity, or
requires hospitalisation or medical or surgical interven-
tion. Though there is evidence that patients can enhance
the measurement of mild adverse events, [65-67] phar-
maco-vigilance in the UK traditionally focuses on prac-
tice-reported adverse events, which are generally more
serious, and provide a more cost-effective monitoring
system.
Health outcomes
We shall use two instruments that are acceptable to elderly
patients. To measure general health status we shall use the
SF-36. To underpin cost-utility analysis we shall use the
EQ5D [68], acceptable to elderly people if one omits the
'thermometer'.
Home interviews
Rather than interview all respondents face to face on all
occasions, we invite able respondents to complete postal
questionnaires, and conduct interviews by telephone
whenever feasible. To this end we have developed criteria
to guide the completion mode appropriate to each
respondent. We shall also take account of completion
mode in our analysis. In particular we shall compare thePage 9 of 14
(page number not for citation purposes)
BMC Health Services Research 2004, 4 http://www.biomedcentral.com/1472-6963/4/11validity, reliability and responsiveness of each data collec-
tion method [62,69].
Will health services research issues be addressed?
The economic evaluation will take the form of an incre-
mental cost-utility analysis from the perspective of both
the NHS and society in general. The main focus of the eco-
nomic evaluation will be the EQ5D. We shall also analyse
other outcomes, in particular the SF-36 and MAI, to estab-
lish whether the choice of measure affects the results of
the economic evaluation.
Given the difficulty of disentangling the costs of pharma-
ceutical care and its sequelae from other costs, economic
analysis will include all health care costs, including hospi-
tal admissions and referrals, ambulance journeys and con-
sultations in primary care and at the pharmacy.
We shall extract data from practice records on medications
prescribed, number and type of consultations in the prac-
tice or at home, outpatient referrals and length of any
inpatient stay. We shall also extract data from pharmacy
records on medications dispensed. All these data will
relate to the period from 12 months before the interven-
tion until 24 months after completion of recruitment. In
addition pharmacists contributing to RESPECT will
complete a questionnaire at baseline to identify the aver-
age time spent dealing with patients like those to be
recruited into RESPECT, both in dispensing medications
and providing advice and support. They will also record
prospectively the contact and non-contact time spent on
the PCP for each patient, as part of that PCP. Patients and
carers will provide data on the costs to themselves in both
time and money of seeking pharmaceutical and other
health care, as well as estimates of time off from normal
activities. They will also provide data on the carer support
they normally receive, including help with taking their
medication and using compliance aids. These data from
patients will serve to validate and enhance the estimates of
health care use derived from practice records. The costs
associated with training general practitioners and phar-
macists will also be assessed, including fixed costs, con-
sumables, patients' time, locum cover and travel costs.
Later sensitivity analysis will allow us to assess the extent
to which the cost-effectiveness of pharmaceutical care
depends on the process of implementation, especially on
the relative increase in pharmacist workload.
We shall derive an annual cost of management for the
control and intervention period for each patient and use
these data to calculate an incremental cost for each
patient. As patients serve as their own control, if a patient
dies during the control period they will not be included in
any of the analysis. If the patient dies during the interven-
tion period, their data will be included in the analysis.
Censored data will be adjusted accordingly using appro-
priate techniques.
Cost-effectiveness will be assessed via the ratio of addi-
tional cost to additional benefit, measured according to
the change in the EQ5D between the control and inter-
vention period. The confidence region surrounding the
average incremental cost effectiveness ratio will be esti-
mated using appropriate statistical techniques such as the
bootstrap method and Monte-Carlo simulation. Stochas-
tic analyses such as this will allow a cost effectiveness
acceptability curve to be generated. This will represent a
plot of the probability of management with a PCP being
more cost-effective than usual care under alternative
assumptions about the threshold cost per QALY. Based on
the average incremental cost, cost-effectiveness ratio and
the uncertainty surrounding the estimates, we will explore
the implications of a widespread implementation of phar-
maceutical care.
What is proposed sample size and justification for power 
calculations?
After losses to follow up the final sample size will be
about 400, viz 20 practices × 20 patients on average or 40
pharmacies × 10 patients on average. It is difficult to esti-
mate the power of this complex design to detect changes
in the MAI, the principal outcome measure. To simplify
this calculation we discount the likely advantages con-
ferred by time series analysis and estimate the power of
analysing the change in the MAI between baseline and
three (or 12) months.
The 400 or more patients completing the proposed trial
will not be a simple random sample, but a sample from
40 or so clusters – the patients who use each of the partic-
ipating pharmacies. If these pharmacies are at all consist-
ent in their approach to pharmaceutical care, findings will
be more homogeneous within them than between them.
The effect of this is to reduce the power of the trial by the
factor [1 + ICCC × (n - 1)], where ICCC is the 'intra-cluster
correlation coefficient' and n is the average cluster size
[70].
Although we know of no data on ICCCs for the MAI, we
have access to the full data set of the North of England
Study of Standards and Performance in General Practice
(1992), [71] including data on practitioners' adherence to
clinical guidelines analogous to the MAI. Since none of
those intra-practice CCs exceeded 0.1 and few exceeded
0.05, we base our preliminary estimate of the power of
RESPECT on an intra-pharmacy CC of 0.1. Since the
average cluster size is 10 (viz 400 divided by 40), the effec-
tive sample size of RESPECT for the MAI could be as low
as 210 (viz 400 divided by 1.9).Page 10 of 14
(page number not for citation purposes)
BMC Health Services Research 2004, 4 http://www.biomedcentral.com/1472-6963/4/11An effective sample size of 210 would yield 80% power
when using a significance level of 5% to detect a difference
in MAI between intervention and control groups of 0.4 of
a standard deviation (SD) [72] – usually regarded as a
moderate effect size. Although we cannot yet estimate the
SD of the MAI within RESPECT, Hanlon's trial reported
that the MAI had an SD close to 10 points [15]. Under
conservative assumptions about loss to follow up and
intra-pharmacy correlation, therefore, RESPECT can
detect a change of four points in the MAI. In contrast
Hanlon's trial achieved a change of five points [15]. The
grant-holders, who include four clinicians, therefore
judge that a change of four points is both achievable and
clinically important.
We cannot yet estimate the SD of EQ-5D scores within
RESPECT. In the general population the EQ-5D has an SD
of the order of 16 points [73]. Although we know of no
data on ICCCs for the EQ-5D, none of the intra-practice
CCs for patient outcomes in the North of England Study
of Standards and Performance in General Practice (1992)
[71] exceeded 0.01. We therefore base our preliminary
estimate of the power of the RESPECT trial to detect
changes in EQ-5D on an IPCC of 0.01. So RESPECT
should have an effective sample size of at least 370 for
outcomes (viz 400 divided by 1.09). This would yield
80% power when using a significance level of 5% to detect
a change in EQ-5D scores equivalent to 0.3 standard devi-
ations, ie about five points. Although the applicants do
not expect much change in generic outcomes following
the introduction of pharmaceutical care, they judge that a
change of five points would indeed be clinically
meaningful.
What is the planned recruitment rate?
There are nearly 150 practices in the East Riding and Selby
& York PCT, all computerised and linked to the NHS net-
work through the East Riding Health Authority. From a
survey of four practices we established that there are more
than enough patients meeting the inclusion criteria for the
trial. In one practice of 8,000 patients, for example, there
were 180 men over 75, of whom 25% took five or more
different drugs. The numbers and proportion of women
were greater. We therefore expect no difficulty in recruit-
ing 35 patients from each practice.
Are there likely to be any problems with compliance?
Compliance with the intervention is unlikely to be a prob-
lem, either by professionals or by patients. We did not
encounter any problems with professional compliance in
a previous study of pharmaceutical care within palliative
care [58]. If a pharmacist leaves a participating branch,
however, we shall ask for a permanent replacement and
give the replacement pharmacist individual training. Fur-
thermore patient compliance with drugs is an outcome
rather than a threat.
What is the likely rate of loss to follow-up?
From East Riding data we estimate that losses from mor-
tality (about 5%), leaving home for institutional care or
elsewhere (about 10%), and non-response to question-
naires (about 20%) will not exceed 40% in total.
How many centres will be involved?
Twenty general practices – four within each of the five
PCTs likely to take part. With the encouragement of the
former East Riding & Hull Health Authority (ERHHA) the
four PCTs within ERHHA have agreed to support the study
and meet excess treatment costs. The Selby and York PCT
has also agreed to do so.
What is the proposed type of analysis?
All analyses will be by 'intention to treat'. Whenever pos-
sible we shall include patients lost to follow up by using
all available data, including those from pharmacies'
patient medication records and general practices' repeat
prescription indices. We shall analyse the five interrupted
time series by the methods expounded by Box and Jenkins
(1976) [74]. Within each time series the analysis will in
effect compare the process and outcome data collected
before training in pharmaceutical care with those col-
lected after that training. Because the definitive analysis
combines these sub-analyses, it is much more robust
against external events like changes in health policy than
a single time series would have been. Nevertheless
because the five PCTs differ in patient characteristics,
notably socio-demographic characteristics, the time series
models for the four main outcome measures will take as
covariates the known risk factors for drug-related adverse
events We shall analyse the five multiple interrupted time
series by the latest Statistical Analysis System Economet-
rics and Time Series (SAS/ETS) procedures [75]. In doing
so we shall distinguish between four levels – PCT, prac-
tice, pharmacy and patient.
Are there any planned subgroup analyses?
To guide the implementation of PC we shall use analysis
of covariance to compare effectiveness and cost-effective-
ness between patients at low risk of adverse events and
those at high risk. The covariates will be age, total number
of drugs, and oral anti-coagulants, hypoglycaemic and
non-steroidal anti-inflammatory drugs [76].
What is the proposed frequency of analyses (including any 
interim analyses)?
Although we shall monitor the incidence of adverse
events throughout the trial, we shall analyse only once
(Figure 1).Page 11 of 14
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We have modelled this trial on two current studies:
A The UK BEAM trial of low back pain in 150 practices
across the UK, of which ITR is principal investigator.
B The feasibility study of the use of pharmaceutical care in
'vulnerable' elderly patients in ERHHA, of which IW, HE
and PDC are co-investigators.
Over what period is funding requested?
42 months (Figure 1)
Details of trial team, trial management and 
participating centres
What are the arrangements for day to day management of 
the trial?
The management structure of RESPECT has been derived
from that successfully adopted by the UK BEAM trial, led
by Ian Russell. Ian Wong will lead RESPECT with support
from Ian Russell in York, and from Peter Campion and the
trial co-ordinator in Hull. The co-ordinator will report
directly to Ian Wong and take day-to-day responsibility
for the conduct of the trial, including fieldwork and liai-
son with practices, pharmacies and patients. Under Ian
Russell's supervision York University will take responsibil-
ity for trial design, remote randomisation, data
management, health economics and statistical analysis.
The Trial Management Group comprising applicants, col-
laborators, trial co-ordinator, research pharmacist, data
manager, economist, statistician and both secretaries will
meet monthly to manage the trial.
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